Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises NeuroNova AB in relation to the merger with Newron Pharmaceuticals S.p.A.
Mandate

Vinge advises NeuroNova AB in relation to the merger with Newron Pharmaceuticals S.p.A.

June 13, 2012

Vinge has advised NeuroNova AB in connection with the merger with Newron Pharmaceuticals S.p.A (”Newron”). NeuroNova AB is a research company within the biotechnology and pharmaceuticals industry which primarily develops therapies for illnesses caused by the death of cells in the central nervous system. Newron is a research company within biotechnology and is listed on the Swiss stock exchange (SIX).

Vinge’s team consisted of, among others, responsible partner Johan Winnerblad and associates Matthias Pannier and Alex Miler.

Related

Vinge advises Vimian in connection with new RCF and issuance of senior unsecured bonds

 Vinge advises Vimian Group AB (publ) (“Vimian”) in connection with a new EUR 330 million multicurrency revolving facility agreement and its issuance of senior unsecured bonds in an amount of EUR 150 million (within a framework of EUR 250 million)
May 28, 2025

Vinge represents Alrik Technologies in connection with their latest funding round

 Vinge has represented Alrik Technologies in connection with their latest funding round led by People Ventures, with Pi Labs doubling down on their investment.
May 27, 2025

Vinge advises Trinax in connection with the acquisition of Struqtur

 Trinax, a Helix Kapital portfolio company, has acquired Struqtur, a Swedish company offering a comprehensive cloud-based software solution for time reporting, project management and work orders.
May 26, 2025